BackgroundSyphilis continues to be a public health problem, and its diagnosis still has limitations. Molecular diagnosis provides an alternative for rapid and effective management. The objective is to determine the accuracy of tests in the molecular diagnosis of syphilis.MethodsWe searched PubMed and Web of Sciences for articles related to molecular detection of syphilis from January 1, 2009, to December 31, 2019. The bivariate Reitsma model and the hierarchical receiver operating characteristic curve model were used to evaluate the diagnostic performance of molecular tests at a 95% confidence interval. A subgroup meta-analysis was performed to explore sources of heterogeneity.ResultsForty-seven articles were identified for qualitative synthesis, of which 23 met the inclusion criteria for meta-analysis. The pooled sensitivities in conventional polymerase chain reaction (PCR) and real-time PCR were 77.52 (59.50–89.01) and 68.43 (54.96–79.39), respectively. The pooled specificities were 98.00 (90.73–99.59) and 98.84 (97.55–99.46), respectively. Ulcer samples had a better performance (sensitivity of 79.88 [69.00–87.62] and specificity of 98.58 [97.25–99.27]), and the major target genes were the polymerase A gene and tpp47 gene.ConclusionsOur work showed that conventional PCR was more widely used than real-time PCR in the diagnosis of syphilis, and ulcers were the best specimens. Sample types and target genes are factors that may influence the quality of the different tests. These results could provide evidence for further work in the direction of providing a more efficient diagnostic test.

In Sub-Saharan Africa, transfusion safety remains a challenge due to the high endemicity of blood-borne infections. This study aimed to determining the seroprevalence of human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV), and Treponema pallidum among blood donors in Ouagadougou. This was a retrospective study in blood donor. HIV 1/2 and HCV antibodies and HBsAg were screened and confirmed with two ELISA (Enzyme Linked ImmunoSorbent Assay). While T. pallidum antibodies were also screened and confirmed with two serology tests. Only samples positive for both tests were counted as positive. Prevalence rates were calculated among first-time blood donors. Of 63,779 registered blood donors, 54,113 (84.84%) were first-time donors. Overall seroprevalences of HIV, HBV, HCV and Treponema pallidum were 2.56%, 11.87%, 5.89% and 3.22% respectively. Seroprevalences of HIV-HBV, HBV-HCV, HBV- T. pallidum and HIV-HBV-HCV co-infections were 0.36; 1.21; 0.54 and 0.02 respectively. The study reports that HIV, HBV, HCV and Treponema pallidum seroprevalences remain high among blood donors. These results highlight a potential infectious risk to blood products recipients.